Access to Medicine Index 2026: Novartis and GSK lead global pharmaceutical industry rankings

The Access to Medicine Foundation has published the tenth edition of its global Access to Medicine Index, assessing how 20 leading research-based pharmaceutical companies are addressing access to essential medicines, vaccines and diagnostic products in 113 low- and middle-income countries (LMICs). The 2026 assessment covers 84 diseases, conditions and pathogens and evaluates company performance against 29 metrics across three technical areas: Governance of Access, Research & Development (R&D) and Product Delivery.

Novartis and GSK retain the leading positions

Novartis secured first place in the 2026 Index, followed by GSK in second position. Both companies ranked first and second, respectively, in the overall assessment and across all three technical areas.

The next six companies performed above the industry average across the technical areas:

  • AstraZeneca — 3rd place
  • Sanofi — 4th place
  • Bayer — 5th place
  • Boehringer Ingelheim — joint 6th place
  • Roche — joint 6th place
  • Pfizer — 8th place

The results highlight the continued leadership of Novartis and GSK in integrating access considerations into pharmaceutical research, corporate governance and product delivery.

Three key findings from the 2026 Index

The Foundation identifies three major developments in the pharmaceutical industry’s approach to access to medicines.

Access planning for pipeline products is improving, but non-communicable diseases remain underserved

Companies are increasingly incorporating access considerations into the development of new products. However, progress remains uneven across disease areas, with access planning for non-communicable diseases (NCDs) continuing to lag behind planning for communicable diseases and neglected tropical diseases.

Across the 357 late-stage R&D projects assessed, 245 (69%) have an access plan in place. Coverage is higher for Phase III projects (84%) than for Phase II projects (51%). Nevertheless, 34 priority diseases remain entirely unaddressed by the R&D pipelines covered by the Index.

Progress in cancer access remains uneven

The report identifies promising developments in improving access to cancer treatments in LMICs. However, these advances have not yet translated into consistent access across the countries and populations covered by the assessment.

Inclusive business models are expanding, but their impact remains difficult to measure

Pharmaceutical companies are increasingly adopting inclusive business models intended to strengthen their long-term presence in underserved markets and improve access to essential healthcare products.

However, limited disclosure of detailed patient-reach data makes it difficult to establish the actual impact of these initiatives on access to treatment.

Performance across the three technical areas

The 2026 Index evaluates pharmaceutical companies across three technical areas, each with a different weighting in the overall assessment: Governance of Access (15%), R&D (30%) and Product Delivery (55%).

Governance of Access

Governance of Access remains the strongest-performing area across the industry. Companies have made progress in integrating access considerations into corporate strategies and strengthening executive-level accountability.

However, the Foundation highlights the need for more consistent measurement and public reporting of patient reach. In the 2026 assessment, 12 of the 20 companies met the updated standard for systematically measuring the number of people reached with their products.

Research & Development

The R&D findings point to a continuing decline in industry engagement with diseases identified as priorities for global health.

The number of companies conducting R&D for priority diseases has fallen to its lowest level since 2018. Research activity remains concentrated in a relatively limited number of disease areas, including HIV, tuberculosis and malaria, while 34 priority diseases have no corresponding development activity among the projects assessed.

Although access planning has become more established during product development, approximately three out of ten projects still lack an access plan.

Product Delivery

Companies continue to perform strongly in capacity building, with all 20 companies implementing health-system-strengthening initiatives designed to address local needs, and most investing in local manufacturing and supply chain capabilities.

Nevertheless, performance varies across other aspects of product delivery, indicating that improvements in manufacturing and supply capabilities do not automatically translate into consistent patient access.

Twenty years of monitoring access to medicines

The 2026 edition marks the tenth publication of the Access to Medicine Index and the twentieth anniversary of the Foundation’s work monitoring pharmaceutical industry efforts to improve access to essential healthcare products.

The accompanying retrospective analysis examines how pharmaceutical companies’ approaches to global health equity and access to medicines have evolved over two decades.

The Foundation’s assessment also provides individual report cards for all 20 companies, identifying their strengths, weaknesses and opportunities to improve access to medicines in underserved markets.

POPULAR